Bangalore-based Strand Life Sciences Pvt Ltd, which focuses on clinical genomics and research in biotechnology, has appointment Scott Storrer as its global president, as per a company release. Storrer, who joined Strand in July 2014 as president of North America, will oversee the company’s operations worldwide.
Storrer has been in the healthcare industry for over two decades. Prior to joining Strand, he was the president and CEO of Genomind, a personalised medicine company. Previously he has held several leadership positions with Cardinal Health, where he advanced to group president of Cardinal’s $81 billion pharmaceutical segment. Earlier in his career, he was executive vice president, service and information technology with Cigna Corp.
He holds a bachelor’s degree in economics and mathematics from DePauw University and an MBA from Boston University.
Strand also introduced its US management team which include Preveen Ramamoorthy, global head of diagnostics; Harsha Rajasimha, vice president of global business development; Doreen Korba, vice president of global marketing; Caely Cusick, vice president of personalised medicine sales and Cheryl Abrantes, manager of client services.
Strand is a genomic profiling company that uses next-generation sequencing (NGS) technology for cancer care. Founded in 2002 by professors of Bangalore-based Indian Institute of Science, it has attracted a slew of investors. Biomark Capital (which split from Burrill & Co) spent $10 million to buy a stake in the company in its Series B round in 2013. The deal had a mix of primary and secondary components in which its previous investors – ITVUS Fund, WestBridge and angel investors exited. The previous investors had invested $3.5 million in 2002.
It opened its own DNA sequence and gene panel wet lab in Bangalore and opened a lab which it operates in the 1,400-bed Mazumdar-Shaw Cancer Centre in Bangalore.
(Edited by Joby Puthuparampil Johnson)